Prevalence of human papillomavirus antibodies in young female subjects in England

被引：42

作者：

Jit, M.

Vyse, A.

Borrow, R.

Pebody, R.

Soldan, K.

Miller, E.

机构：

[1] Hlth Protect Agcy, Ctr Infect, Immunisat Dept, London NW9 5HT, England

[2] Hlth Protect Agcy, Ctr Infect, Modelling & Econ Unit, London NW9 5HT, England

[3] Manchester Royal Infirm, Hlth Protect Agcy NW Lab, Vaccine Evaluat Unit, Manchester M13 9WL, Lancs, England

[4] Hlth Protect Agcy, Ctr Infect, HIV & STI Dept, London NW9 5HT, England

来源：

BRITISH JOURNAL OF CANCER | 2007年 / 97卷 / 07期

关键词：

England; female; papillomavirus; human; seroepidemiologic studies;

D O I：

10.1038/sj.bjc.6603955

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Sera from 1483 female subjects in England aged 10-29 years were tested. The age-standardised seroprevalence was 10.7% (95% confidence intervals 9.0-12.3) for human papillomavirus (HPV) 6, 2.7% (1.8-3.6) for HPV 11, 11.9% (10.2-13.6) for HPV 16, 4.7% (3.5-5.8) for HPV 18, and 20.7% (18.6-22.7) for any of the four types.

引用

收藏

页码：989 / 991

页数：3

相关论文

共 18 条

[1]

Af Geijersstam V, 1999, INT J CANCER, V80, P489, DOI 10.1002/(SICI)1097-0215(19990209)80:4<489::AID-IJC1>3.0.CO

[2]

2-9

[3] Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].

Carter, JJ ;

Koutsky, LA ;

Hughes, JP ;

Lee, SK ;

Kuypers, J ;

Kiviat, N ;

Galloway, DA .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919

[4] Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18 [J].

Dias, D ;

Van Doren, J ;

Schlottmann, S ;

Kelly, S ;

Puchalski, D ;

Ruiz, W ;

Boerckel, P ;

Kessler, J ;

Antonello, JM ;

Green, T ;

Brown, M ;

Smith, J ;

Chirmule, N ;

Barr, E ;

Jansen, KU ;

Esser, MT .

CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) :959-969

[5] The serological response to papillomaviruses [J].

Dillner, J .

SEMINARS IN CANCER BIOLOGY, 1999, 9 (06) :423-430

[6] Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses [J].

Ferguson, M ;

Heath, A ;

Johnes, S ;

Pagliusi, S ;

Dillner, J .

INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (06) :1508-1514

[7] Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial [J].

Harper, DM ;

Franco, EL ;

Wheeler, C ;

Ferris, DG ;

Jenkins, D ;

Schuind, A ;

Zahaf, T ;

Innis, B ;

Naud, P ;

De Carvalho, NS ;

Roteli-Martins, CM ;

Teixeira, J ;

Blatter, MM ;

Korn, AP ;

Quint, W ;

Dubin, G .

LANCET, 2004, 364 (9447) :1757-1765

[8] A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia [J].

Kelly, H ;

Riddell, MA ;

Gidding, HF ;

Nolan, T ;

Gilbert, GL .

VACCINE, 2002, 20 (25-26) :3130-3136

[9] HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial [J].

Kitchener, H. C. ;

Almonte, M. ;

Wheeler, P. ;

Desai, M. ;

Gilham, C. ;

Bailey, A. ;

Sargent, A. ;

Peto, J. .

BRITISH JOURNAL OF CANCER, 2006, 95 (01) :56-61

[10] Updating the natural history of HPV and anogenital cancer [J].

Moscicki, Anna-Barbara ;

Schiffman, Mark ;

Kjaer, Susanne ;

Villa, Luisa L. .

VACCINE, 2006, 24 :42-51